SynthesisFrontiers in cardiovascular medicine2025
Prognostic value of epicardial adipose tissue in heart failure: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Heart's Hidden Influencer: Epicardial Adipose Tissue in the Pathogenesis of Heart Failure.Cardiology discovery · 2026Review
- Role of systemic and epicardial adipose tissue in cardiometabolic disease.Nature reviews. Cardiology · 2026Review
- The Volume and Density of Epicardial Adipose Tissue Measured by Computed Tomography as Markers of the Effects of Cardiovascular Disease Risk Factors.Journal of cardiovascular development and disease · 2026Article
- Dapagliflozin effect on pericardial fat deposition: lessons from the DAPA EAT.Heart failure reviews · 2026Review
- Epicardial adipose tissue volume stratifies atrial fibrillation subtypes in reduced ejection fraction heart failure: a CT-based predictor.Frontiers in cardiovascular medicine · 2026Article
- Epicardial adipose tissue in cardiovascular diseases: a potential therapeutic target.Frontiers in cardiovascular medicine · 2026Review
- The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential.Current cardiology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epicardial adipose tissue (EAT) essentially affects the pathophysiologic development of heart failure (HF), while existing research has not well elucidated its prognostic value for outcome. The present study aims at including relevant studies for systematically assessing its prognostic value in HF patients. Methods: The studies assessing the way EAT was employed to predict adverse HF outcomes were included from PubMed, Web of Science, Embase, and the Cochrane Library databases, and relevant data were accurately extracted. The primary outcome included the composite outcome of HF hospitalization and all-cause mortality (ACM). Secondary outcomes were the composite outcome of cardiovascular death and HF hospitalization and HF rehospitalization. We combined the standard mean difference (SMD) of EAT in HF patients with and without adverse events (AEs) and the EAT to adverse outcome hazard ratio (HR). Results: The nine included studies involved 1,939 HF patients and 329 control populations. HF patients with AEs presented a higher EAT vs. those without (SMD: 3.33, CI: 0.96-5.69, Conclusion: EAT is considered a clinical predictor of the composite outcome of HF hospitalization and ACM and may contribute to the prediction of poor prognosis in HF patients. Systematic Review Registration: https://www.crd.york.ac.uk/, identifier [CRD420250653252].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.